Use of ECMO before hospital discharge · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in use of ECMO before hospital discharge compared with severe criteria (moderate certainty).
1 finding from 1 review
Progression to severe criteria · respiratory failure in infants born at or near term
Inhaled NO at moderate probably leads to lower progression to severe criteria compared with severe criteria (moderate certainty).
1 finding from 1 review
Neurodevelopmental disability at 18 to 24 months among survivors · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in neurodevelopmental disability at 18 to 24 months among survivors compared with severe criteria (moderate certainty).
1 finding from 1 review
Death or requirement for ECMO · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in death or requirement for ECMO compared with severe criteria (low certainty).
1 finding from 1 review
Mortality before hospital discharge · respiratory failure in infants born at or near term
Inhaled NO at moderate showed no clear difference in death before hospital discharge compared with severe criteria (moderate certainty).
1 finding from 1 review
Clinical Failure (children with a severe to moderate overall clinical assessment score at two hours) · patients with acute asthma
IV + inhaled beta agonist probably leads to lower clinical Failure (children with a severe to moderate overall… compared with inhaled beta‐agonist (moderate certainty).
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Death or moderate/severe disability at 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or moderate/severe disability at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Adverse events (moderate) · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
It is very uncertain whether summary of findings: Inhaled antibiotics plus IV antibiotics changes adverse events moderate adverse events experienced during and after… compared with IV antibiotics only (very low certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 5452(6 RCTs)
The intervention showed no clear difference in moderate to severe exacerbations ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of… (high certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 3184(3 RCTs)
The intervention probably leads to lower moderate to severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of… (moderate certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 2037(2 RCTs)
The intervention leads to lower moderate to severe exacerbations ‐ HD TRIPLE vs MD‐ICS/LABA№ of… (high certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2651(2 RCTs)
The intervention showed no clear difference in moderate to severe exacerbations ‐ MD TRIPLE vs HD‐ICS/LABA№ of… (low certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 4989(4 RCTs)
The intervention leads to lower moderate to severe exacerbations ‐ HD TRIPLE vs HD‐ICS/LABA№ of… (high certainty).
1 finding from 1 review
Intervention not reported
Moderate to severe exacerbations ‐ HD TRIPLE vs MD TRIPLE№ of participants: 3470(3 RCTs)
The intervention showed no clear difference in moderate to severe exacerbations ‐ HD TRIPLE vs MD TRIPLE№ of… (moderate certainty).
1 finding from 1 review